Studies in mouse models have validated that KRASG12D inhibitors, KRASG12V inhibitors, and the Pan-RAS inhibitor exhibit synergistic anti-tumor effects when combined with EGFR monoclonal antibodies. The gene discussed is EGFR; the disease is neoplasm.